CooperVision’s Brilliant Futures Myopia Management Program Expands Globally


SAN RAMON, Calif.—Less than a year after the U.S. debut of its Brilliant Futures Myopia Management Program, featuring the MiSight 1 day contact lens, CooperVision is now expanding the comprehensive approach to multiple countries, including the U.K. Russia, Spain, Portugal, Canada, South Korea and Taiwan. The program seeks to create a new standard of care by creating the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty, CooperVision said in a statement. “Several years from now, I believe we will look back at late 2020 as an inflection point in the global myopia management movement,” said Daniel McBride, president of CooperVision.

“Never before has there been this degree of momentum, driven in large part by substantial investments CooperVision is making in evidence-based science, innovative products, and comprehensive clinical and practice management education in the form of Brilliant Futures. Partnering with the optometry, ophthalmology and pediatric health communities, we have a real opportunity to change the lives of countless children in the decades ahead,” McBride said.

Brilliant Futures has attracted robust participation during its selective U.S. rollout, with more than 1,500 eyecare professionals now certified to fit MiSight 1 day, according to CooperVision. MiSight 1 day is the first and only soft contact lens the U.S. FDA has approved for slowing the progression of myopia in children between 8 and 12 years old. During the past several weeks, a nationwide parent-focused advertising campaign featuring entrepreneur and actress Sarah Michelle Gellar further accelerated adoption.

CooperVision also reported that MiSight 1 day is making inroads in China, where myopia has increased significantly in recent years, particularly among children and teenagers. In mid-October, the Center for Medical Device Evaluation of China’s National Medical Products Administration (NMPA) granted priority review status to MiSight 1 day’s approval submission.

In addition to ensuring faster evaluation of the application, the priority status provides more opportunities for company representatives to interact with the medical experts assessing MiSight 1 day’s safety and efficacy data, CooperVision said. No myopia control product currently has NMPA approval, including spectacles and atropine.